HER2+ Breast Cancer

Erika P. Hamilton, MD, discusses updated data from the phase 2 HER2CLIMB trial examining tucatinib in patients with HER2-positive breast cancer and brain metastases.

Joyce A. O'Shaughnessy, MD, discusses the utility of tucatinib in HER2-positive breast cancer with brain metastases.

Erika P. Hamilton, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Novel antibody-drug conjugates introduce promising options for the management of patients with HER2-positive breast cancer; however, management of drug-related toxicities and optimal sequencing of HER2-targeted therapies remains an ongoing challenge.

Ado-trastuzumab emtansine demonstrated a consistent invasive disease-free survival benefit versus trastuzumab in patients with HER2-positive breast cancer across all biomarker subgroups evaluated in the pivotal phase 3 KATHERINE trial.

Sara A. Hurvitz, MD, discusses unmet needs within the field of HER2-positive breast cancer.

Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast cancers.

Sara A. Hurvitz, MD, discusses the lack of predictive biomarkers in HER2-positive breast cancer.

Brian Czerniecki, MD, PhD, discusses the benefit of tucatinib in patients with HER2-positive breast cancer and brain metastases.

The FDA has approved the new VENTANA HER2 Dual ISH DNA Probe Cocktail test for use as a companion diagnostic for trastuzumab and to detect HER2 mutations in patients with breast cancer.

Adam M. Brufsky, MD, PhD, further discusses the utility of trastuzumab deruxtecan in HER2-positive breast cancer, ongoing research efforts examining the antibody–drug conjugate, and how he approaches sequencing in the paradigm.

The growing number of treatments within the HER2-positive breast cancer armamentarium signals a need to redefine and tailor neoadjuvant and adjuvant strategies to individual patients.

The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.

Charles E. Geyer, Jr, MD, discusses the state of HER2-positive breast cancer, the significance of the results of the DESTINY-Breast01 trial, and symptoms that could be an early indicator of interstitial lung disease.

Nancy U. Lin, MD, discusses the treatment landscape in HER2-positive metastatic breast cancer. 

Anthracycline-based chemotherapy followed by ado-trastuzumab emtansine plus pertuzumab did not show statistically significant or clinically meaningful improvement in invasive disease-free survival in patients with high-risk HER2-positive early breast cancer, missing the primary end point of the phase 3 KAITLIN trial.

Heather Han, MD, discusses ongoing clinical trials within the field of HER2-positive breast cancer and the future of personalized treatment for this patient population.

Brian Czerniecki, MD, PhD, discusses treatment options for patients with HER2-positive breast cancer who have brain metastases.

William J. Gradishar, MD, discusses the activity of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and the importance of building experience with the drug before evaluating it in combination or moving it into earlier lines of therapy.

Nancy U. Lin, MD, discusses the development of systemic therapies for the treatment of patients with metastatic HER2-positive breast cancer and brain metastases.

Kamran A. Ahmed, MD, discusses the evolution of treatment for patients with breast cancer brain metastases, recent pivotal findings that have significantly improved survival for these patients, and a number of agents on the horizon.

Brian Czerniecki, MD, PhD, discusses how patients with metastatic HER2-positive breast cancer who later develop central nervous system metastases comprise a large population of all patients with breast cancer, and there continue to be an unmet need for this subgroup.

The FDA has approved a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) with hyaluronidase, administered via subcutaneous injection in combination with intravenous chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.

The HER2-selective TKI tucatinib (Tukysa) demonstrated potent antitumor activity alone and in combination with ado-trastuzumab emtansine (T-DM1; Kadcyla) in HER2-overexpressing breast cancer cell lines and xenograft models.

William R. Gwin III, MD, discusses the ongoing trial examining this novel combination and provided insight into the next steps for this research.